Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less
Hepatitis C Treatment-as-prevention In The Prison Setting
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The burden of hepatitis C virus (HCV) infection in Australia is rising with prison settings being a major reservoir of HCV infection. This study evaluates the feasibility of a rapid scale-up of a new highly effective, short and tolerable HCV therapy and its impact on HCV transmission in the prison setting. This is the first HCV treatment-as-prevention study in prisons having strong potentials to inform public health policy nationally and internationally.
Reducing The Health, Social And Economic Burden Of Injecting Drug Use In Australia
Funder
National Health and Medical Research Council
Funding Amount
$2,606,037.00
Summary
Injecting drug use (IDU) is a disproportionately large source of health and social harm. This CRE unites Australia’s leading scientists in the IDU field – researchers working on blood-borne virus epidemiology and treatment, overdose prevention, justice health and psychiatric health - and experts from key non-government organisations. The CRE will develop new ways to improve the health of injecting drug users, and reduce the health and social burden of IDU to the Australian community.
Injecting Drug Use, Incarceration, Infection: Investigating Opportunities For Public Health Interventions In Disadvantaged Populations
Funder
National Health and Medical Research Council
Funding Amount
$329,564.00
Summary
New knowledge required to address infectious diseases and mental illness among two disadvantaged and overlapping groups -people who inject drugs (PWID) and prisoners – will be produced: Cross sectional and longitudinal studies will examine HIV risk in specific populations; A system to track the emergence of injecting will be developed; The global scale of mental illness and TB among PWID will be determined; and how to improve coverage and delivery of TB prevention and treatment will be explored.
Innovative Approaches To Reducing The Impact Of Blood Borne Viruses And Sexually Transmitted Infections On Young People.
Funder
National Health and Medical Research Council
Funding Amount
$246,859.00
Summary
Over the next 5 years I will undertake a program of research centred on reducing the impact of blood-borne viruses (BBVs) and sexually transmitted infections (STIs) in vulnerable populations, particularly young people. I will study how these infections are transmitted, associated risk behaviours including drug and alcohol use and sexual risk, and develop interventions to improve the detection and management of infected individuals.
Behavioural, Virological And Immunological Factors Influencing Hepatitis C Virus Infection In Injecting Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$963,437.00
Summary
The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the viru ....The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the virus is spreading. Consensus is emerging that the best hope for control of HCV and related disease lies in a vaccine; our research will lay much of the groundwork for its development. The applicants' research to date shows that IDUs are being infected with HCV more frequently than previously assumed, that many carry multiple strains, and that dominant strains vary rapidly in individuals over time. These results reinforce the view that our prevention methods will not reduce infection rates and that current anti-viral treatments are not the solution. Nevertheless, we also found that some IDUs remain free of HCV infection despite risky behaviour with infected associates; intensive study of the immune functioning of these persistently non-infected individuals holds promise for vaccine development. In our proposed research, a collaboration of leading Australian epidemiologists, virologists and immunologists, we will recruit 210 young IDUs and follow them regularly for two years. Recruits will describe their social networks and nominate IDUs with whom they inject, provide blood samples and be interviewed about their behaviour at 3-month intervals. Individuals with recent and resolved HCV infection, change of dominant strain and lack of infection despite risky behaviour will be identified and their blood analysed for genetic factors that may be linked to immune protection. The outcomes will be crucial to the development and trialling of a vaccine against HCV.Read moreRead less